TARAProtara Therapeutics, Inc.
- GlobeNewswire
Protara Therapeutics Announces Third Quarter 2026 Financial Results and Provides a Business Update
Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial of TARA-002 in NMIBC by year-end 2026 Enrollment in registrational STARBORN-1 trial now expected to complete in ...
- GlobeNewswire
Protara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral Support
Company remains on track to report interim results from Phase 2b cohort in 4Q 2026 NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage biotechnology company ...
- GlobeNewswire
Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that ...
- GlobeNewswire
Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 4Q 2026 The ADVANCED-3 trial is being redesigned as an exploratory trial to expand into and accelerate data in ...
- Analyst Upgrades
Oppenheimer Maintains Outperform on Protara Therapeutics, Raises Price Target to $28
Oppenheimer analyst Leland Gershell maintains Protara Therapeutics with a Outperform and raises the price target from $25 to $28. ...
- GlobeNewswire
Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage biotechnology company committed to advancing transformative therapies for the treatment of cancer and rare diseases, ...
- GlobeNewswire
Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026
Event will provide an overview of Lymphatic Malformations, the treatment landscape and the TARA-002 clinical program NEW YORK, May 18, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a ...
- GlobeNewswire
Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC
TARA-002 demonstrates 72% complete response rate at any time, 67% complete response rate at the 6-month landmark and 55% complete response rate at the 12-month landmark in BCG-Naïve patients Favorable safety ...
- Analyst Upgrades
JP Morgan Maintains Overweight on Protara Therapeutics, Lowers Price Target to $26
JP Morgan analyst Brian Cheng maintains Protara Therapeutics with a Overweight and lowers the price target from $27 to $26. ...
- GlobeNewswire
Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
The Company intends to submit a Biologics License Application (BLA) for TARA-002 in Lymphatic Malformations (LMs) in 2H 2027 Hosting virtual investor webinar discussing LMs program with key opinion leader (KOL) ...
- Analyst Upgrades
HC Wainwright & Co. Maintains Buy on Protara Therapeutics, Raises Price Target to $27
HC Wainwright & Co. analyst Andrew S. Fein maintains Protara Therapeutics with a Buy and raises the price target from $23 to $27. ...
- GlobeNewswire
Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage biotechnology company developing transformative therapies for the treatment of cancer and rare diseases, today ...
- GlobeNewswire
Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
Reported interim data from ADVANCED-2 trial in non-muscle invasive bladder cancer (NMIBC); TARA-002 demonstrated 68% complete response rate at six months in BCG-Unresponsive patients Company expects to complete ...
- Analyst Upgrades
JP Morgan Initiates Coverage On Protara Therapeutics with Overweight Rating, Announces Price Target of $27
JP Morgan analyst Brian Cheng initiates coverage on Protara Therapeutics with a Overweight rating and announces Price Target of $27. ...
- GlobeNewswire
TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse events Company expects to complete enrollment of the BCG-Unresponsive cohort of the ADVANCED-2 trial in 2H 2026 Company ...
- GlobeNewswire
Protara Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that ...
- Analyst Upgrades
HC Wainwright & Co. Reiterates Buy on Protara Therapeutics, Maintains $23 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Protara Therapeutics with a Buy and maintains $23 price target. ...
- GlobeNewswire
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA) ("Protara" or the "Company"), a clinical-stage company developing transformative therapies for the treatment of cancer and rare ...
- GlobeNewswire
Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium
NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that ...
- GlobeNewswire
Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones
On track to report interim results from approximately 25 six-month evaluable BCG-Unresponsive patients in ADVANCED-2 trial in Q1 2026 Received Breakthrough Therapy and Fast Track designations for TARA-002 in LMs; ...
- Analyst Upgrades
Piper Sandler Initiates Coverage On Protara Therapeutics with Overweight Rating, Announces Price Target of $24
Piper Sandler analyst Kelsey Goodwin initiates coverage on Protara Therapeutics with a Overweight rating and announces Price Target of $24. ...
- GlobeNewswire
Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that ...
- GlobeNewswire
Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations
NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that the ...
- GlobeNewswire
Protara Announces Closing of $75 Million Public Offering
NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA) ("Protara"), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today ...
- GlobeNewswire
Protara Announces Proposed Public Offering
NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA) ("Protara"), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today ...